NCT03650491: Phase 1: A Study of FOR46 in Patients With Relapsed or Refractory Multiple Myeloma
Updated: Jun 22, 2022
NCT03650491: Phase 1: A Study of FOR46 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
This study will test the safety and efficacy of FOR46 given every 21 days to patients with relapsed or refractory multiple myeloma.
The name of the study drug involved in this study is: FOR46 for Injection
Sponsor
Multiple Locations
Official Title: A Phase I Study of FOR46 Administered Every 21 Days in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
First Posted : August 28, 2018
Drug: FOR46
Anti-CD46 Antibody-drug Conjugate FOR46 (Code C156416)
ADC FOR46
Anti-CD46 ADC FOR46
Anti-CD46 Antibody-drug Conjugate FOR46
Antibody-drug Conjugate FOR46
CD46-ADC FOR46
FOR 46
FOR-46
FOR46
Locations
United States, California
United States, Colorado
United States, Georgia
United States, Maryland
United States, Michigan
United States, Missouri
United States, New York